# OnCo record exam (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/exam/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "exam", "NCT00704730" ;
  schema:name "EXAM"@en ;
  schema:description "EXAM showed that cabozantinib, which blocks RET, MET and VEGF receptors, held back progressive medullary thyroid cancer for far longer than placebo, and gave the disease its second approved targeted drug."@en ;
  schema:url <https://onco.cc/trials/exam/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00704730> ;
  onco:status "positive" ;
  onco:tag "subtype-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/medullary-thyroid-cancer/>, <https://onco.cc/cancers/thyroid/> ;
  onco:drugs <https://onco.cc/drugs/cabozantinib/> ;
  onco:companies <https://onco.cc/companies/exelixis/> ;
  onco:people <https://onco.cc/people/rossella-elisei/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-exam-cabozantinib-mtc-elisei-jco-2013/> .